Top

Published in:

01-12-2014

Role of MTA2 in human cancer

Authors: Kyle R. Covington, Suzanne A. W. Fuqua

Published in: Cancer and Metastasis Reviews | Issue 4/2014

Abstract

Metastasis is the ultimate cause of death for most cancer patients. While many mechanisms have been delineated for regulation of growth and tumor initiation of the primary tumor, very little is known about the process of metastasis. Metastasis requires dynamic alteration of cellular processes in order for cells to disseminate from the primary tumor to distant sites. These alterations often involve dramatic changes in the regulation of cytoskeletal and cell-environment interactions. Furthermore, controlled refinement of these interactions requires feedback to regulatory networks in the nucleus. MTA2 is a member of the metastasis tumor-associated family of transcriptional regulators and is a central component of the nucleosome remodeling and histone deacetylation complex. MTA2 acts as a central hub for cytoskeletal organization and transcription and provides a link between nuclear and cytoskeletal organization. We will focus on MTA2 in this chapter, especially its role in breast cancer metastasis.

The UniProt Consortium. (2014). Activities at the Universal Protein Resource (UniProt). Nucleic Acids Research, 42(D1), D191–D198. doi:10.1093/nar/gkt1140.PubMedCentralCrossRef

Dephoure, N., Zhou, C., Villén, J., Beausoleil, S. A., Bakalarski, C. E., Elledge, S. J., & Gygi, S. P. (2008). A quantitative atlas of mitotic phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 105(31), 10762–10767. doi:10.1073/pnas.0805139105.PubMedCentralPubMedCrossRef

Mayya, V., Lundgren, D. H., Hwang, S.-I., Rezaul, K., Wu, L., Eng, J. K., & Han, D. K. (2009). Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Science Signaling, 2(84), ra46. doi:10.1126/scisignal.2000007.PubMedCrossRef

Olsen, J. V., Vermeulen, M., Santamaria, A., Kumar, C., Miller, M. L., Jensen, L. J., & Mann, M. (2010). Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Science Signaling, 3(104), ra3. doi:10.1126/scisignal.2000475.PubMedCrossRef

Rigbolt, K. T. G., Prokhorova, T. A., Akimov, V., Henningsen, J., Johansen, P. T., Kratchmarova, I., & Blagoev, B. (2011). System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Science Signaling, 4(164), rs3. doi:10.1126/scisignal.2001570.PubMedCrossRef

Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., & Mann, M. (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science (New York, N.Y.), 325(5942), 834–840. doi:10.1126/science.1175371.CrossRef

Callebaut, I., Courvalin, J. C., & Mornon, J. P. (1999). The BAH (bromo-adjacent homology) domain: a link between DNA methylation, replication and transcriptional regulation. FEBS Letters, 446(1), 189–193.PubMedCrossRef

Boyer, L. A., Latek, R. R., & Peterson, C. L. (2004). The SANT domain: a unique histone-tail-binding module? Nature Reviews. Molecular Cell Biology, 5(2), 158–163. doi:10.1038/nrm1314.PubMedCrossRef

Aasland, R., Stewart, A. F., & Gibson, T. (1996). The SANT domain: a putative DNA-binding domain in the SWI-SNF and ADA complexes, the transcriptional co-repressor N-CoR and TFIIIB. Trends in Biochemical Sciences, 21(3), 87–88.PubMed

10.

Solari, F., Bateman, A., & Ahringer, J. (1999). The Caenorhabditis elegans genes egl-27 and egr-1 are similar to MTA1, a member of a chromatin regulatory complex, and are redundantly required for embryonic patterning. Development (Cambridge, England), 126(11), 2483–2494.

11.

Luo, J., Su, F., Chen, D., Shiloh, A., & Gu, W. (2000). Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature, 408(6810), 377–381. doi:10.1038/35042612.PubMedCrossRef

12.

Cui, Y., Niu, A., Pestell, R., Kumar, R., Curran, E. M., Liu, Y., & Fuqua, S. A. W. (2006). Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells. Molecular Endocrinology, 20(9), 2020–2035. doi:10.1210/me.2005-0063.PubMedCrossRef

13.

Kumar, R., Wang, R.-A., & Bagheri-Yarmand, R. (2003). Emerging roles of MTA family members in human cancers. Seminar in Oncology, 30(5 Suppl 16), 30–37.CrossRef

14.

Bowen, N. J., Fujita, N., Kajita, M., & Wade, P. A. (2004). Mi-2/NuRD: multiple complexes for many purposes. Biochimica et Biophysica Acta, 1677(1–3), 52–57. doi:10.1016/j.bbaexp.2003.10.010.PubMedCrossRef

15.

Lai, A. Y., & Wade, P. A. (2011). Cancer biology and NuRD: a multifaceted chromatin remodelling complex. Nature Reviews Cancer, 11(8), 588–596. doi:10.1038/nrc3091.PubMedCentralPubMedCrossRef

16.

Moon, H.-E., Cheon, H., Chun, K.-H., Lee, S. K., Kim, Y.-S., Jung, B.-K., & Lee, M.-S. (2006). Metastasis-associated protein 1 enhances angiogenesis by stabilization of HIF-1alpha. Oncology Reports, 16(4), 929–935.PubMed

17.

Singh, R. R., & Kumar, R. (2007). MTA family of transcriptional metaregulators in mammary gland morphogenesis and breast cancer. Journal of Mammary Gland Biology and Neoplasia, 12(2–3), 115–125. doi:10.1007/s10911-007-9043-7.PubMedCrossRef

18.

Barone, I., Brusco, L., Gu, G., Selever, J., Beyer, A., Covington, K. R., & Fuqua, S. A. W. (2011). Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α. Journal of the National Cancer Institute, 103(7), 538–552. doi:10.1093/jnci/djr058.PubMedCentralPubMedCrossRef

19.

Covington, K. R., Brusco, L., Barone, I., Tsimelzon, A., Selever, J., Corona-Rodriguez, A., & Fuqua, S. A. W. (2013). Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. Breast Cancer Research and Treatment. doi:10.1007/s10549-013-2709-5.PubMed

20.

Fujita, N., Jaye, D. L., Kajita, M., Geigerman, C., Moreno, C. S., & Wade, P. A. (2003). MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell, 113(2), 207–219.PubMedCrossRef

21.

Fujita, N., Kajita, M., Taysavang, P., & Wade, P. A. (2004). Hormonal regulation of metastasis-associated protein 3 transcription in breast cancer cells. Molecular Endocrinology, 18(12), 2937–2949. doi:10.1210/me.2004-0258.PubMedCrossRef

22.

Zhang, H., Stephens, L. C., & Kumar, R. (2006). Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clinical Cancer Research, 12(5), 1479–1486. doi:10.1158/1078-0432.CCR-05-1519.PubMedCrossRef

23.

Fidler, I. J. (1990). Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Research, 50(19), 6130–6138.PubMed

24.

Psaila, B., Kaplan, R. N., Port, E. R., & Lyden, D. (2006). Priming the “soil” for breast cancer metastasis: the pre-metastatic niche. Breast Disease, 26, 65–74.PubMed

25.

Kaplan, R. N., Psaila, B., & Lyden, D. (2006). Bone marrow cells in the “pre-metastatic niche”: within bone and beyond. Cancer Metastasis Reviews, 25(4), 521–529. doi:10.1007/s10555-006-9036-9.PubMedCrossRef

26.

Fidler, I. J. (1970). Metastasis: guantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2’-deoxyuridine. Journal of the National Cancer Institute, 45(4), 773–782.PubMed

27.

Fidler, I. J., & Kripke, M. L. (1977). Metastasis results from preexisting variant cells within a malignant tumor. Science, 197(4306), 893–895.PubMedCrossRef

28.

Buyse, M., Loi, S., Veer, L., van’t Viale, G., Delorenzi, M., Glas, A. M., & Consortium, T. R. A. N. S. B. I. G. (2006). Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. Journal of the National Cancer Institute, 98(17), 1183–1192.PubMedCrossRef

29.

Sabatier, R., Finetti, P., Cervera, N., Lambaudie, E., Esterni, B., Mamessier, E., & Bertucci, F. (2011). A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Research and Treatment, 126(2), 407–420. doi:10.1007/s10549-010-0897-9.PubMedCrossRef

30.

Blick, T., Hugo, H., Widodo, E., Waltham, M., Pinto, C., Mani, S. A., & Thompson, E. W. (2010). Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. Journal of Mammary Gland Biology and Neoplasia, 15(2), 235–252. doi:10.1007/s10911-010-9175-z.PubMedCrossRef

31.

Alves, C. C., Carneiro, F., Hoefler, H., & Becker, K.-F. (2009). Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Frontiers in Bioscience, 14, 3035–3050.CrossRef

32.

Yamazaki, D., Kurisu, S., & Takenawa, T. (2005). Regulation of cancer cell motility through actin reorganization. Cancer Science, 96(7), 379–386. doi:10.1111/j.1349-7006.2005.00062.x.PubMedCrossRef

33.

Wolf, K., Mazo, I., Leung, H., Engelke, K., von Andrian, U. H., Deryugina, E. I., & Friedl, P. (2003). Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. The Journal of Cell Biology, 160(2), 267–277. doi:10.1083/jcb.200209006.PubMedCentralPubMedCrossRef

34.

Carr, H. S., Zuo, Y., Oh, W., & Frost, J. A. (2013). Regulation of focal adhesion kinase activation, breast cancer cell motility, and amoeboid invasion by the RhoA guanine nucleotide exchange factor Net1. Molecular and Cellular Biology, 33(14), 2773–2786. doi:10.1128/MCB.00175-13.PubMedCentralPubMedCrossRef

35.

Narumiya, S., Tanji, M., & Ishizaki, T. (2009). Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Reviews, 28(1–2), 65–76. doi:10.1007/s10555-008-9170-7.PubMedCrossRef

36.

Cavallo, F., De Giovanni, C., Nanni, P., Forni, G., & Lollini, P.-L. (2011). 2011: the immune hallmarks of cancer. Cancer Immunology, Immunotherapy: CII, 60(3), 319–326. doi:10.1007/s00262-010-0968-0.PubMedCentralPubMedCrossRef

37.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674. doi:10.1016/j.cell.2011.02.013.PubMedCrossRef

38.

Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57–70.PubMedCrossRef

39.

Meng, S., Tripathy, D., Frenkel, E. P., Shete, S., Naftalis, E. Z., Huth, J. F., & Uhr, J. W. (2004). Circulating tumor cells in patients with breast cancer dormancy. Clinical Cancer Research, 10(24), 8152–8162. doi:10.1158/1078-0432.CCR-04-1110.PubMedCrossRef

40.

Schackmann, R. C. J., van Amersfoort, M., Haarhuis, J. H. I., Vlug, E. J., Halim, V. A., Roodhart, J. M. L., & Derksen, P. W. B. (2011). Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. Journal of Clinical Investigation, 121(8), 3176–3188. doi:10.1172/JCI41695.PubMedCentralPubMedCrossRef

41.

Fu, J., Qin, L., He, T., Qin, J., Hong, J., Wong, J., & Xu, J. (2011). The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Research, 21(2), 275–289. doi:10.1038/cr.2010.118.PubMedCentralPubMedCrossRef

42.

(EBCTCG), E. B. C. T. C. G, Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., & Peto, R. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378(9793), 771–784. doi:10.1016/S0140-6736(11)60993-8.PubMedCrossRef

43.

Goss, P. E., & Chambers, A. F. (2010). Does tumour dormancy offer a therapeutic target? Nature Reviews Cancer, 10(12), 871–877. doi:10.1038/nrc2933.PubMedCrossRef

44.

Heyn, C., Ronald, J. A., Ramadan, S. S., Snir, J. A., Barry, A. M., MacKenzie, L. T., & Foster, P. J. (2006). In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain. Magnetic Resonance in Medicine, 56(5), 1001–1010. doi:10.1002/mrm.21029.PubMedCrossRef

45.

Riethdorf, S., & Pantel, K. (2008). Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology, 75(2), 140–148. doi:10.1159/000123852.PubMedCrossRef

46.

Kedrin, D., van Rheenen, J., Hernandez, L., Condeelis, J., & Segall, J. E. (2007). Cell motility and cytoskeletal regulation in invasion and metastasis. Journal of Mammary Gland Biology and Neoplasia, 12(2–3), 143–152. doi:10.1007/s10911-007-9046-4.PubMedCrossRef

47.

Wang, Y., Zhang, H., Chen, Y., Sun, Y., Yang, F., Yu, W., & Shang, Y. (2009). LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell, 138(4), 660–672. doi:10.1016/j.cell.2009.05.050.PubMedCrossRef

48.

Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011). Molecular signatures database (MSigDB) 3.0. Bioinformatics, 27(12), 1739–1740. doi:10.1093/bioinformatics/btr260.PubMedCentralPubMedCrossRef

49.

Amano, M., Nakayama, M., & Kaibuchi, K. (2010). Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken), 67(9), 545–554. doi:10.1002/cm.20472.CrossRef

50.

Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., & Weinberg, R. A. (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell, 117(7), 927–939.PubMedCrossRef

51.

Casas, E., Kim, J., Bendesky, A., Ohno-Machado, L., Wolfe, C. J., & Yang, J. (2011). Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Research, 71(1), 245–254. doi:10.1158/0008-5472.CAN-10-2330.PubMedCentralPubMedCrossRef

52.

Vansteenkiste, J., Cutsem, E. V., Dumez, H., Chen, C., Ricker, J. L., Randolph, S. S., & Schöffski, P. (2008). Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Investigational New Drugs, 26(5), 483–488. doi:10.1007/s10637-008-9131-6.PubMedCrossRef

53.

Pulford, B., Reim, N., Bell, A., Veatch, J., Forster, G., Bender, H., & Zabel, M. D. (2010). Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures. PLoS One, 5(6), e11085. doi:10.1371/journal.pone.0011085.PubMedCentralPubMedCrossRef

54.

Liu, G. J., Wang, Z. J., Wang, Y. F., Xu, L. L., Wang, X. L., Liu, Y., & Zeng, Y. J. (2012). Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. European Journal of Clinical Pharmacology, 68(2), 131–139. doi:10.1007/s00228-011-1100-x.PubMedCrossRef

55.

Ying, H., Biroc, S. L., Li, W.-W., Alicke, B., Xuan, J.-A., Pagila, R., & Dinter, H. (2006). The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Molecular Cancer Therapeutics, 5(9), 2158–2164. doi:10.1158/1535-7163.MCT-05-0440.PubMedCrossRef

Title: Role of MTA2 in human cancer
Authors: Kyle R. Covington
Suzanne A. W. Fuqua
Publication date: 01-12-2014
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 4/2014
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-014-9518-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Sugars in the microenvironment: the sticky problem of HA turnover in tumors

MTA1—a stress response protein: a master regulator of gene expression and cancer cell behavior

Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy

New approaches to selectively target cancer-associated matrix metalloproteinase activity

Metastatic tumor antigen in hepatocellular carcinoma: golden roads toward personalized medicine

Physiological functions of MTA family of proteins

Keynote webinar | Spotlight on antibody–drug conjugates in cancer